Visualizing cancer in a different light
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) — NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for Gleolan, an optical imaging agent for the visualization of tumor tissue in patients undergoing surgical resection for meningioma.
“We are pleased to initiate this landmark study evaluating the utility of fluorescence-guided surgery (FGS) in the meningioma patient population. We are excited about the execution of this important study as we continue to expand the use of Gleolan in cancer surgeries around the world,” said Alan M. Ezrin, Ph.D.,…
Dr. Christian Ramsey first neurosurgeon in state to use GleolanTM for enhanced visualization of high-grade gliomas/glioblastoma
NX Development Corp. (NXDC) Launches FDA-Approved GleolanTM (aminolevulinic acid HCl) for Enhanced Visualization of High-Grade Gliomas (including Glioblastomas).
NX Development Corp (NXDC), a privately-held life sciences company, today announced a Merger Acquisition as a result of which NXDC has become a wholly-owned subsidiary of photonamic GmbH & Co. KG